Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial.
Reporting directly to the Chief Medical Officer, in this role you will lead the team(s) responsible for the development and implementation of the scientific and clinical strategy and plans for key Jounce programs as they transition from the preclinical to clinical stage, working in close partnership with a senior program manager. The successful candidate will have a proven track record in effectively leading biologics drug development teams as well as a strong scientific and/or clinical background preferably in immuno-oncology or a closely related therapeutic area.
To apply, please visit https://careers-jouncetx.icims.com